NBIX · Neurocrine Biosciences Inc
Price
Snapshot
50 fields · last close| Market Cap | $15.82B |
| P/E | 22.42 |
| Float | 99.35M |
| Beta | 0.36 |
| Volatility | 8.9% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 77 |
| Price | 155.64 |
| Change | +0.00% |
| Prev Close | 155.64 |
| Open | 158.24 |
| Day Low | 154.83 |
| Day High | 159.80 |
| Avg Vol | 1 |
| Avg $ Vol | $159.7M |
| 52W High | 186.12 |
| 52W Low | 122.14 |
| 52W Pos | 52.4% |
| From High | −16.38% |
| From Low | +27.43% |
| Max DD 1Y | −20.90% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +0.02% |
| SMA 50 | −6.17% |
| SMA 200 | +5.49% |
| RSI (14) | 44.1 |
| Vol 30D | 40.8% |
| Vol 90D | 36.8% |
| 1Y Range | 122–186 |
| Daily bars | 507 |
| Perf Week | +1.03% |
| Perf Month | −2.62% |
| Perf Quarter | −5.03% |
| Perf Half Y | +21.47% |
| Perf Year | +10.85% |
| Perf YTD | +10.70% |
| Prev Day | +0.00% |
| Clavix | B |
| Debt / Eq | 0.00 |
| Curr Ratio | 3.39 |
| Int Cover | 3.0× |
| FCF Margin | 26.0% |
| Rev Growth | +39.5% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 8 / 35 |
Clavix risk grade
regraded every trading dayNBIX grades B, 77 of 100. Steadiest on Macro Resilience (70), most exposed on Price Stability (59, mixed). 3 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 8 of 35 in Biotechnology by Clavix score.
How rough the ride is
| NBIX | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.36 | 0.50 |
| Volatilityannualized | 8.9% | 13.2% |
| Max drawdown, past yearworst peak-to-trough fall | −20.9% | — |
| Typical daily movemedian absolute daily change | 1.12% | — |
| Days beyond ±3%of the last 252 sessions | 2711% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| NBIX | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.36 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| NBIX | |
|---|---|
| 1 week | +1.0% |
| 1 month | −2.6% |
| Year to date | +10.7% |
| 1 year | +10.9% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| NBIX | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 31 Jul |
| Average score0 most bearish, 100 most bullish | 61 |
| Bullish · bearisharticles above 60 · below 40 | 23 · 5 |
| Directionarticles whose tone is improving vs worsening | 23 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| NBIX | |
|---|---|
| Revenue growthyear over year | +39.5% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Biotechnology
36 companies| Metric | NBIX | Sector spread | Median |
|---|---|---|---|
| Beta | 0.36 | 0.50 | |
| Volatility | 8.9% | 13.2% | |
| P/E | 22.42 | 22.42 | |
| Debt / equity | 0.00 | 0.24 | |
| Current ratio | 3.39 | 3.73 | |
| FCF margin | 26.0% | 29.1% | |
| Interest coverage | 3.0× | -0.2× |
Recent news
most recent scored articles · the chip is the article’s score · click to openNeurocrine Biosciences (NBIX), having acquired Soleno Therapeutics (maker of VYKAT XR) earlier this year, sent a letter from CEO Kyle Gano to the Prader-Willi Syndrome community introducing the company and outlining plans, including a new study launching in Q1 2027 focused on people with PWS-related hyperphagia (extreme hunger) and complex health issues such as severe obesity.
Neurocrine's drug Crenessity is gaining rapid traction in congenital adrenal hyperplasia (CAH), with sales rising sharply and most eligible patients not yet treated, leaving room for further growth.
The FDA cleared Neurocrine Biosciences to start a mid-stage (Phase 2) human trial of its drug NBI-1117567, being tested to improve cognition in Alzheimer's patients through its Nxera partnership. The stock is down 14.72% over the past 30 days, though up 10.90% year-to-date and 12.22% over the past year.
Neurocrine Biosciences' partner Nxera Pharma announced that the FDA accepted the application to begin human trials of NBI-1117567, an experimental pill aimed at improving cognition in Alzheimer's patients, which triggered a $10 million milestone payment to Nxera.
Neurocrine Biosciences said the FDA accepted its application to begin a mid-stage (Phase 2) clinical trial of its drug NBI-1117567 in patients with cognitive problems linked to Alzheimer's disease.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ASND | Ascendis Pharma A/S | B+ | $16.88B | 19.59 | 0.38 | Compare |
| BBIO | BridgeBio Pharma Inc | B | $14.63B | — | 0.96 | Compare |
| EXEL | Exelixis Inc | B+ | $14.62B | 16.99 | 0.48 | Compare |
| HALO | Halozyme Therapeutics Inc | B | $12.51B | 30.24 | 0.96 | Compare |
| MDGL | Madrigal Pharmaceuticals Inc | B | $12.50B | — | -1.10 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $12.20B | — | 1.30 | Compare |
| UTHR | United Therapeutics Corp | A- | $21.89B | 15.88 | 0.51 | Compare |
| KRYS | Krystal Biotech Inc | B | $10.60B | 43.91 | 0.55 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.